Restart Life Sciences Corp. logo

Restart Life Sciences Corp. (NMLSF)

Market Closed
7 Jul, 13:31
OTC PINK OTC PINK
$
0. 06
+0.01
+14.75%
$
1.16M Market Cap
- P/E Ratio
0% Div Yield
160 Volume
0 Eps
$ 0.05
Previous Close
Day Range
0.06 0.06
Year Range
0.02 0.12
Want to track NMLSF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NMLSF closed yesterday higher at $0.06, an increase of 14.75% from Friday's close, completing a monthly increase of 33.33% or $0.01. Over the past 12 months, NMLSF stock gained 89.33%.
NMLSF is not paying dividends to its shareholders.
The last earnings report, released on May 27, 2025, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports.
Restart Life Sciences Corp. has completed 2 stock splits, with the recent split occurring on Jan 24, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

NMLSF Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Restart Life Sciences Corp. Dividends

NMLSF is not paying dividends to its shareholders.

Restart Life Sciences Corp. Earnings

27 May 2025 Date
-
Cons. EPS
-
EPS
27 Nov 2024 Date
-
Cons. EPS
-
EPS
29 Aug 2024 Date
-
Cons. EPS
-
EPS
26 Aug 2024 Date
-
Cons. EPS
-
EPS
30 May 2024 Date
-
Cons. EPS
-
EPS
NMLSF is not paying dividends to its shareholders.
27 May 2025 Date
-
Cons. EPS
-
EPS
27 Nov 2024 Date
-
Cons. EPS
-
EPS
29 Aug 2024 Date
-
Cons. EPS
-
EPS
26 Aug 2024 Date
-
Cons. EPS
-
EPS
30 May 2024 Date
-
Cons. EPS
-
EPS

Restart Life Sciences Corp. (NMLSF) FAQ

What is the stock price today?

The current price is $0.06.

On which exchange is it traded?

Restart Life Sciences Corp. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is NMLSF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 1.16M.

Has Restart Life Sciences Corp. ever had a stock split?

Restart Life Sciences Corp. had 2 splits and the recent split was on Jan 24, 2025.

Restart Life Sciences Corp. Profile

Biotechnology Industry
Healthcare Sector
Mr. Steve Loutskou CEO
OTC PINK Exchange
66980V106 Cusip
CA Country
- Employees
- Last Dividend
26 Jun 2020 Last Split
- IPO Date

Overview

Nova Mentis Life Science Corp., operating globally, emerges as a pioneering biotechnology entity dedicated to the forefront of therapeutic and diagnostic advancements. Initially founded in 2004 and formerly known as Liberty Leaf Holdings Ltd., the company underwent a significant rebranding to Nova Mentis Life Science Corp. in June 2020, marking a new chapter in its mission. With its headquarters in Vancouver, Canada, the organization's strategic operations span the development of state-of-the-art diagnostics and psilocybin-based therapeutics, targeting neuroinflammatory conditions with a laser focus on autism spectrum disorder and fragile X syndrome. This ambitious endeavor is bolstered by a collaborative research agreement with the University of Central Florida (UCF), aiming to pioneer a saliva serotonin assay, a testament to the company's commitment to groundbreaking scientific research.

Products and Services

  • Psilocybin-based Therapeutics

    At the heart of Nova Mentis Life Science Corp.'s product pipeline lies its innovative psilocybin-based therapeutics. This cutting-edge treatment is designed to target neuroinflammatory conditions, with a significant emphasis on autism spectrum disorder and fragile X syndrome. Leveraging the psychedelic compound psilocybin, the company strives to unlock new therapeutic possibilities, aiming to alleviate symptoms and improve the quality of life for individuals affected by these conditions.

  • Saliva Serotonin Assay Development

    In collaboration with the University of Central Florida (UCF), Nova Mentis is in the process of developing a groundbreaking saliva serotonin assay. This diagnostic tool represents a significant leap forward in the non-invasive measurement of serotonin levels, a crucial neurotransmitter involved in mood regulation, digestion, sleep, and cognition. The assay is tailored for individuals with neuroinflammatory conditions, particularly focusing on autism spectrum disorder and fragile X syndrome, offering a promising avenue for early detection and personalized treatment strategies.

Contact Information

Address: 700-838 West Hasting Street
Phone: 778-819-0244